Reuters logo
BRIEF-Peregrine Pharma presents data for Bavituximab's anti-tumor enhancing activity
April 4, 2017 / 1:02 PM / 8 months ago

BRIEF-Peregrine Pharma presents data for Bavituximab's anti-tumor enhancing activity

April 4 (Reuters) - Peregrine Pharmaceuticals Inc

* Peregrine Pharmaceuticals highlights clinical data presentation at aacr 2017 annual meeting supporting potential of Bavituximab to enhance anti-tumor activity of immunotherapy

* Peregrine Pharma- data showed for patients in study’s Bavituximab plus docetaxel treatment arm who received subsequent immunotherapy, mos was not reached

* Peregrine Pharmaceuticals Inc - mos was 13.0 months for patients in study’s placebo plus docetaxel arm who received subsequent immunotherapy Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below